RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Qualitative Genetic Test
Comprehensive Introduction to Genetic Leukemia Testing
The RUNX1-RUNX1T1 AML1-ETO t(8;21) Qualitative test represents a breakthrough in molecular diagnostics for acute myeloid leukemia. This sophisticated genetic analysis detects the specific chromosomal translocation that characterizes a distinct subtype of AML, providing clinicians with critical information for accurate diagnosis, prognosis assessment, and treatment monitoring. The test’s precision in identifying this genetic abnormality makes it an essential tool in modern hematological practice.
What This Advanced Genetic Test Measures
This specialized diagnostic test specifically detects the presence of the RUNX1-RUNX1T1 fusion gene resulting from the t(8;21) chromosomal translocation. The test measures:
- The genetic fusion between RUNX1 on chromosome 21 and RUNX1T1 on chromosome 8
- Presence of the AML1-ETO fusion transcript
- Qualitative detection of this leukemia-specific genetic marker
- Genetic abnormalities associated with core-binding factor acute myeloid leukemia
Technical Methodology
Utilizing cutting-edge Real Time PCR technology, this test provides exceptional sensitivity and specificity in detecting the genetic fusion. The methodology ensures accurate identification of even low levels of the fusion transcript, making it valuable for both initial diagnosis and minimal residual disease monitoring.
Who Should Consider This Genetic Test
This test is recommended for individuals presenting with:
- Suspected acute myeloid leukemia based on clinical symptoms
- Unexplained cytopenias or abnormal blood counts
- Patients with previously diagnosed AML requiring genetic characterization
- Individuals undergoing treatment monitoring for AML
- Patients being evaluated for minimal residual disease assessment
- Those with family history of hematological malignancies
Clinical Indications and Symptoms
Patients experiencing fatigue, recurrent infections, unexplained bruising or bleeding, bone pain, or abnormal complete blood count results should discuss this test with their healthcare provider. Early detection of specific genetic abnormalities can significantly impact treatment decisions and outcomes.
Significant Benefits of Genetic Testing
Undergoing the RUNX1-RUNX1T1 genetic test provides multiple advantages:
- Accurate Diagnosis: Precise identification of AML subtypes for targeted treatment
- Prognostic Information: Understanding disease progression and treatment response
- Treatment Guidance: Informing chemotherapy and targeted therapy decisions
- Monitoring Capability: Tracking treatment effectiveness and disease recurrence
- Personalized Medicine: Enabling tailored treatment approaches based on genetic profile
- Early Intervention: Facilitating timely treatment initiation for better outcomes
Understanding Your Test Results
Your genetic test results will be interpreted by our expert molecular pathologists:
- Positive Result: Indicates presence of the RUNX1-RUNX1T1 fusion gene, confirming the specific AML subtype
- Negative Result: Suggests absence of this particular genetic abnormality, though other AML subtypes may be present
- Quantitative Interpretation: Results are provided with clinical context and recommendations
- Follow-up Guidance: Detailed explanation of next steps and potential treatment implications
Clinical Correlation
It’s important to understand that test results should be interpreted in conjunction with clinical findings, complete blood counts, bone marrow morphology, and other diagnostic information. Our genetic counselors are available to help you understand your results and their implications.
Test Pricing and Service Information
| Service | Price (USD) |
|---|---|
| Discount Price | $112 |
| Regular Price | $150 |
Service Details
- Turnaround Time: 3-4 days
- Sample Type: Bone marrow / Peripheral blood (Transport immediately)
- Test Components: EDTA Vacutainer (2ml)
- Methodology: Real Time PCR
Pre-Test Instructions
The RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Qualitative test requires a Doctor’s prescription. Prescription requirements do not apply for surgery and pregnancy cases or individuals planning international travel. Please consult with your healthcare provider to obtain the necessary documentation.
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, with convenient locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and numerous other cities. Our nationwide network ensures accessible genetic testing services for patients throughout the country.
Schedule Your Genetic Test Today
Take the first step toward precise leukemia diagnosis and personalized treatment planning. Our experienced genetic specialists are ready to assist you with comprehensive testing services and professional guidance.
Book your appointment now: Call or WhatsApp us at +1(267) 388-9828
Don’t wait to get the critical genetic information you need for informed healthcare decisions. Contact GGC DNA today to schedule your RUNX1-RUNX1T1 genetic test and take control of your hematological health.
